United States · Bill · HR
H.R. 5850 (118th)
To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.
Introduced
29 September 2023
Last action
—
Status
Referred to the Subcommittee on Health.
Sponsors
—
Subjects
Discovery layer
Source updated
24 July 2024
Records
Official bill H.R. 5850 (118th) from United States at United States Congress. Dated 29 September 2023. Status: Referred to the Subcommittee on Health..
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
2 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 29 September 2023
Introduced in House (PDF)
Introduced in House · EN · 29 September 2023
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/118th-congress/house-bill/5850
- Open data entity: https://api.congress.gov/v3/bill/118/hr/5850